Contact this trialFirst, we need to learn more about you.
Selective Estrogen Receptor Modulator
AC699 for Breast Cancer
Recruiting1 awardPhase 1
Sarasota, Florida
This trial is testing AC699, a new oral drug, in patients with a specific type of advanced breast cancer. AC699 works by breaking down estrogen receptors, which helps to stop the cancer from growing. Another drug being tested is AZD9496, which also targets estrogen receptors to prevent cancer growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.